Fiduciary Management Inc. WI Lowers Stock Position in Fresenius Medical Care AG & Co. KGaA $FMS

Key Points

• Fiduciary Management Inc. WI decreased its stake in Fresenius Medical Care AG & Co. KGaA by 5.7%, ending the first quarter with approximately 5.95 million shares valued at $148.2 million.
• Recent analyst evaluations show a shift in sentiment with Zacks Research downgrading the company from a "strong-buy" to a "hold" rating amidst several other mixed reviews.
• The company reported earnings of $0.52 per share, exceeding expectations, with quarterly revenues reaching $5.54 billion, significantly above forecasts of $5 billion.

Fiduciary Management Inc. WI reduced its stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Free Report) by 5.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,950,011 shares of the company's stock after selling 358,652 shares during the quarter. Fiduciary Management Inc. WI owned about 1.01% of Fresenius Medical Care AG & Co. KGaA worth $148,155,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in FMS. Northern Trust Corp lifted its position in Fresenius Medical Care AG & Co. KGaA by 5.0% in the 1st quarter. Northern Trust Corp now owns 380,251 shares of the company's stock worth $9,468,000 after buying an additional 18,061 shares in the last quarter. Brooklyn Investment Group raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 424.5% in the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company's stock worth $32,000 after buying an additional 1,040 shares in the last quarter. Summit Securities Group LLC bought a new position in Fresenius Medical Care AG & Co. KGaA during the 1st quarter valued at about $396,000. Corient IA LLC bought a new position in shares of Fresenius Medical Care AG & Co. KGaA in the first quarter valued at about $622,000. Finally, Raymond James Financial Inc. lifted its position in shares of Fresenius Medical Care AG & Co. KGaA by 1,508.1% during the first quarter. Raymond James Financial Inc. now owns 287,751 shares of the company's stock worth $7,165,000 after purchasing an additional 269,857 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Stock Performance

FMS stock traded down $0.33 during midday trading on Wednesday, hitting $25.15. The company's stock had a trading volume of 168,589 shares, compared to its average volume of 357,706. The company has a quick ratio of 1.08, a current ratio of 1.44 and a debt-to-equity ratio of 0.44. The stock's 50-day moving average price is $26.32 and its 200 day moving average price is $25.82. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $18.94 and a 1 year high of $30.46.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.50 by $0.02. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.75% and a net margin of 3.39%.The business had revenue of $5.54 billion during the quarter, compared to the consensus estimate of $5 billion. As a group, research analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Wall Street Zen raised Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "strong-buy" rating in a research note on Friday, August 22nd. Zacks Research lowered shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 18th. Morgan Stanley restated an "underweight" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 12th. Finally, Truist Financial lifted their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.00 to $30.00 and gave the stock a "hold" rating in a research note on Monday, May 12th. One investment analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $27.80.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.